Abstract
Adverse side effects or toxicities of a drug were previously regarded as a manifestation of drug’s own characterizations, such as the chemical structure and property of a drug. More recently, increasing experimental or clinical data and modern ideas suggest that human’s genetic factors also play indispensable roles in resulting neural side effects of a drug, especially in antidepressant-induced suicide and antibiotics-induced hearing loss. However, there are many questions and technological obstacles (including high costs and limited samples) in these kinds of researches and this makes genetic study of drug toxicities in its initial stage. In this review, we in depth address and analysis of this matter from some new perspectives and propose some new initiatives to improve this type of researches in future. It is also highly needed to expedite the translation of these pharmacogenetic concepts from bench to bedside.
Keywords: Side effects of drug, human genome, neural toxicity, antidepressant, antibiotics, genetics, drug develop, drug safety, medicinal chemistry, genomic study, pharmacogenomics, mental toxicity
Central Nervous System Agents in Medicinal Chemistry
Title:Genetics in Neural Toxicities of Drugs
Volume: 12 Issue: 4
Author(s): Da-Yong Lu, Ting-Ren Lu and Peng-Peng Zhu
Affiliation:
Keywords: Side effects of drug, human genome, neural toxicity, antidepressant, antibiotics, genetics, drug develop, drug safety, medicinal chemistry, genomic study, pharmacogenomics, mental toxicity
Abstract: Adverse side effects or toxicities of a drug were previously regarded as a manifestation of drug’s own characterizations, such as the chemical structure and property of a drug. More recently, increasing experimental or clinical data and modern ideas suggest that human’s genetic factors also play indispensable roles in resulting neural side effects of a drug, especially in antidepressant-induced suicide and antibiotics-induced hearing loss. However, there are many questions and technological obstacles (including high costs and limited samples) in these kinds of researches and this makes genetic study of drug toxicities in its initial stage. In this review, we in depth address and analysis of this matter from some new perspectives and propose some new initiatives to improve this type of researches in future. It is also highly needed to expedite the translation of these pharmacogenetic concepts from bench to bedside.
Export Options
About this article
Cite this article as:
Lu Da-Yong, Lu Ting-Ren and Zhu Peng-Peng, Genetics in Neural Toxicities of Drugs, Central Nervous System Agents in Medicinal Chemistry 2012; 12 (4) . https://dx.doi.org/10.2174/187152412803760591
DOI https://dx.doi.org/10.2174/187152412803760591 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Coronary Artery Disease and Endothelial Dysfunction: Novel Diagnostic and Therapeutic Approaches
Current Medicinal Chemistry Natural Animal Models of Neurodegenerative Protein Misfolding Diseases
Current Pharmaceutical Design Hybrid Molecules Synergistically Acting Against Protein Aggregation Diseases
Current Topics in Medicinal Chemistry Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology Interleukin-18, From Neuroinflammation to Alzheimers Disease
Current Pharmaceutical Design Transplantation of Genetically Modified Haematopoietic Stem Cells to Induce Antigen-Specific Tolerance as a Cure for Autoimmune Diseases
Current Stem Cell Research & Therapy Phytol a Natural Diterpenoid with Pharmacological Applications on Central Nervous System: A Review
Recent Patents on Biotechnology Towards the Molecular Foundations of Glutamatergic-targeted Antidepressants
Current Neuropharmacology MicroRNAs in CAG Trinucleotide Repeat Expansion Disorders: an Integrated Review of the Literature
CNS & Neurological Disorders - Drug Targets Plasma Angiotensin-(1-7) is a Potential Biomarker for Alzheimer’s Disease
Current Neurovascular Research Epigenetics, Depression and Antidepressant Treatment
Current Pharmaceutical Design Phenolic Compounds, Antioxidant Properties and Enzyme Inhibition Ability of Adiantum capillus veneris L. linked to Alzheimer’s Disease, Diabetes Mellitus and Skin Disorders
Current Organic Chemistry Cholinesterases: Roles in the Brain During Health and Disease
Current Alzheimer Research Regulatory Cascade of Neuronal Loss and Glucose Metabolism
CNS & Neurological Disorders - Drug Targets Indandione and Its Derivatives - Chemical Compounds with High Biological Potential
Mini-Reviews in Medicinal Chemistry Ventilatory Support in Persistent Pulmonary Hypertension of the Newborn
Current Respiratory Medicine Reviews Beyond the HapMap Genotypic Data: Prospects of Deep Resequencing Projects
Current Bioinformatics Nuclear Receptors CAR and PXR in Metabolism and Elimination of Drugs
Current Pharmacogenomics Rofecoxib in Patients with Mild Cognitive Impairment: Further Analyses of Data from a Randomized, Double-Blind, Trial
Current Alzheimer Research Design and Development of Signal Transduction Inhibitors for Cancer Treatment: Experience and Challenges with Kinase Targets
Current Signal Transduction Therapy